Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Lantern Pharma (NASDAQ: LTRN) will host a webcast on August 8, 2022, at 4:30 PM ET to discuss its Q2 financial results and future milestones. The company, focused on oncology drug discovery using its proprietary RADR® AI platform, is developing four drug candidates and an ADC program. Lantern aims to identify patients likely to respond to its therapies. Panna Sharma, CEO, will lead the discussion. A replay will be available on their investor relations website.
Lantern Pharma (NASDAQ: LTRN) has received FDA clearance to initiate the Harmonic™ trial, a Phase 2 clinical study for LP-300 in never smokers with advanced non-small cell lung cancer (NSCLC). The trial will enroll 90 patients and evaluate the drug in combination with chemotherapy, building on previous successes where LP-300 demonstrated a 91% overall survival and a 125% two-year survival for this demographic. Enrollment is expected to start in Q3 2022, targeting an estimated market of $1.5 to $2 billion for NSCLC.
Lantern Pharma (NASDAQ: LTRN) announced a virtual key opinion leader (KOL) webinar on May 26, 2022, at 12:00 p.m. ET. The webinar will focus on glioblastoma multiforme (GBM) and the potential of their drug candidate LP-184 for treating GBM and other brain cancers. Experts Dr. John Laterra and Dr. Matthias Holdhoff from Johns Hopkins will lead discussions alongside Lantern's Chief Scientific Officer, Dr. Kishor Bhatia. The event coincides with Brain Tumor Awareness Month, highlighting the urgent need for effective treatments for brain cancers.
Lantern Pharma Inc. (NASDAQ: LTRN) announced its participation in five upcoming investor and scientific conferences in
Lantern Pharma (NASDAQ: LTRN) reported Q1 2022 financial results, revealing $65.2 million in cash and equivalents. The company utilizes its RADR® A.I. platform, which surpassed 20 billion data points, enhancing drug discovery capabilities. The HARMONIC™ Phase 2 trial for LP-300 is expected to enroll patients in Summer 2022. Lantern plans to submit an IND for LP-184 by Q3 2022, targeting solid tumors. R&D expenses increased to $2.7 million from $1.3 million year-over-year. A net loss of $4.1 million was recorded, up from $2.5 million in Q1 2021.
Lantern Pharma (NASDAQ: LTRN) announced Dr. Maria L. Maccecchini as a nominee for its Board of Directors during the Annual Meeting on June 8, 2022. Dr. Maccecchini, a seasoned biopharmaceutical executive, brings decades of experience, particularly in neurodegenerative diseases. Concurrently, Leslie W. Kreis, Jr. will not seek reelection. Lantern's President, Panna Sharma, emphasized Dr. Maccecchini's potential contributions to ongoing clinical trials. Lantern is focused on utilizing its RADR® platform to enhance oncology drug development.
Lantern Pharma (NASDAQ: LTRN) plans to release its Q1 2022 financial results on May 3, 2022, after market closure. Management will host a conference call at 4:30 PM ET to discuss these results and outline future milestones. Lantern Pharma utilizes its RADR® A.I. platform in oncology drug development, focusing on genomically-targeted therapeutics. Currently, the company is developing four drug candidates and an ADC program spanning nine tumor targets, with a commitment to optimize patient outcomes.
Lantern Pharma (NASDAQ:LTRN) will be featured on The RedChip Money Report on Bloomberg TV on April 16 at 7 p.m. ET. This program, which reaches approximately 73 million U.S. households, focuses on small-cap investing and includes interviews with company executives and Wall Street analysts. Lantern Pharma utilizes its RADR® AI platform for oncology drug discovery, with a pipeline of four drug candidates and an ADC program targeting eight tumor types, including two in phase 2 trials.
Lantern Pharma (NASDAQ: LTRN) announced an extension of its share repurchase program through July 31, 2022, allowing for the acquisition of up to $7 million in common stock. Since November 2021, the program has seen the repurchase of 475,157 shares at a cost of approximately $3.4 million. An additional $3.6 million is available for future purchases. As of December 31, 2021, the company reported $70.7 million in cash and equivalents, indicating strong liquidity to support the buyback initiative.
Lantern Pharma (NASDAQ: LTRN) announced promising preclinical data for its drug candidate LP-184 at the upcoming AACR annual meeting, scheduled for April 8-13, 2022. LP-184 showed significant anti-tumor activity in brain metastases models from lung, skin, and breast cancers, achieving 6 times greater potency than standard therapies. This small molecule drug targets DNA in cancer cells, particularly beneficial for patients with CNS cancers due to its favorable blood-brain barrier permeability. The FDA has granted LP-184 Orphan Drug and Rare Pediatric Disease designations, expediting its path toward clinical trials.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
